[go: up one dir, main page]

MX2015015051A - Formulaciones alternativas para polipeptidos de fusion tnfr:fc. - Google Patents

Formulaciones alternativas para polipeptidos de fusion tnfr:fc.

Info

Publication number
MX2015015051A
MX2015015051A MX2015015051A MX2015015051A MX2015015051A MX 2015015051 A MX2015015051 A MX 2015015051A MX 2015015051 A MX2015015051 A MX 2015015051A MX 2015015051 A MX2015015051 A MX 2015015051A MX 2015015051 A MX2015015051 A MX 2015015051A
Authority
MX
Mexico
Prior art keywords
tnfr
fusion polypeptides
alternative formulations
polypeptides
formulations
Prior art date
Application number
MX2015015051A
Other languages
English (en)
Inventor
Cédric Bes
Carlos Bañado
Tamal Raha
Original Assignee
Mabxience S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50732113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015015051(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mabxience S A filed Critical Mabxience S A
Publication of MX2015015051A publication Critical patent/MX2015015051A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)

Abstract

La presente invención se relaciona con composiciones farmacéuticas estables acuosas adecuadas para almacenamiento de polipéptidos que contienen TNFR:Fc.
MX2015015051A 2013-05-02 2014-04-29 Formulaciones alternativas para polipeptidos de fusion tnfr:fc. MX2015015051A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13166230 2013-05-02
EP13166228 2013-05-02
EP13180169 2013-08-13
PCT/EP2014/058695 WO2014177548A1 (en) 2013-05-02 2014-04-29 Alternative formulations for tnfr: fc fusion polypeptides

Publications (1)

Publication Number Publication Date
MX2015015051A true MX2015015051A (es) 2016-06-10

Family

ID=50732113

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015051A MX2015015051A (es) 2013-05-02 2014-04-29 Formulaciones alternativas para polipeptidos de fusion tnfr:fc.

Country Status (16)

Country Link
US (1) US20160106844A1 (es)
EP (1) EP2991668A1 (es)
JP (2) JP2016518386A (es)
KR (1) KR20160008575A (es)
CN (1) CN105873601A (es)
AU (1) AU2014261477A1 (es)
BR (1) BR112015027764A2 (es)
CA (1) CA2911068A1 (es)
EC (1) ECSP15050386A (es)
HK (1) HK1221163A1 (es)
MX (1) MX2015015051A (es)
RU (1) RU2663727C2 (es)
SG (1) SG11201508900UA (es)
TW (2) TW201534349A (es)
UY (2) UY35549A (es)
WO (1) WO2014177548A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
US20180110856A1 (en) * 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical Formulations and Methods of Making the Same
US11236146B2 (en) 2016-10-28 2022-02-01 Celltrion Inc. Stable pharmaceutical formulation
GB201717966D0 (en) * 2017-10-31 2017-12-13 Xenikos Bv Immunotoxins, formulations thereof and their use in medicine
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
GB201901547D0 (en) * 2019-02-05 2019-03-27 Arecor Ltd Stabilized Fc Fusion protein solutions
CN110495447A (zh) * 2019-09-10 2019-11-26 湖南思为康医药有限公司 一种免疫细胞玻璃化冻存保护液及冻存免疫细胞的方法
CA3234491A1 (en) * 2021-10-08 2023-04-13 Kashiv Biosciences, Llc Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1478394T3 (da) * 2002-02-27 2008-10-13 Immunex Corp Stabiliseret TNFR-Fc formulation med arginin
US20080071063A1 (en) * 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
RU2600847C2 (ru) * 2010-05-10 2016-10-27 Интас Биофармасьютикалс Лимитед Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина
WO2012143418A1 (en) * 2011-04-20 2012-10-26 Sandoz Ag STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
AU2012279205B2 (en) * 2011-07-01 2017-08-31 Biogen Ma Inc. Arginine - free TNFR : Fc- fusion polypeptide compositions and methods of use
US10493151B2 (en) * 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
US9302002B2 (en) * 2011-10-18 2016-04-05 Coherus Biosciences, Inc. Etanercept formulations stabilized with combinations of sugars and polyols
CA2878508A1 (en) * 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
PL2919801T3 (pl) * 2012-10-26 2021-01-25 Lupin Atlantis Holdings, Sa Stabilna kompozycja farmaceutyczna białka fuzyjnego TNFR:FC etanerceptu
US9649383B2 (en) * 2012-11-19 2017-05-16 Merck Sharp & Dohme Corp. Liquid formulations for TNFR:Fc fusion proteins

Also Published As

Publication number Publication date
EP2991668A1 (en) 2016-03-09
WO2014177548A1 (en) 2014-11-06
SG11201508900UA (en) 2015-11-27
KR20160008575A (ko) 2016-01-22
US20160106844A1 (en) 2016-04-21
HK1221163A1 (zh) 2017-05-26
BR112015027764A2 (pt) 2017-08-29
AU2014261477A1 (en) 2015-11-19
UY35549A (es) 2014-11-28
RU2663727C2 (ru) 2018-08-08
JP2018109064A (ja) 2018-07-12
ECSP15050386A (es) 2015-12-31
TW201534349A (zh) 2015-09-16
JP2016518386A (ja) 2016-06-23
TW201540321A (zh) 2015-11-01
UY35811A (es) 2015-05-29
RU2015151606A (ru) 2017-06-06
CN105873601A (zh) 2016-08-17
CA2911068A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
MX2015015051A (es) Formulaciones alternativas para polipeptidos de fusion tnfr:fc.
EA201991715A1 (ru) Композиции, содержащие антитело к pdl1
MX2022011140A (es) Metodos novedosos.
IL244206A0 (en) A pharmaceutical preparation containing a pyrimidine compound as an active ingredient
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
EA201791717A1 (ru) Стабильные водные составы адалимумаба
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX368455B (es) Compuestos de tetrahidropirazolopirimidina.
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
IN2015DN03029A (es)
MY173521A (en) Trpv4 antagonists
MX2015012416A (es) Compuestos heterociclicos y sus usos.
AU2018253594A1 (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods
PL2919801T3 (pl) Stabilna kompozycja farmaceutyczna białka fuzyjnego TNFR:FC etanerceptu
IN2013MU03641A (es)
EA201501163A1 (ru) Модуляторы рецептора cxcr7
SG11201608845PA (en) Cosmetic composition containing mentha haplocalyx as active ingredient
SG11201508621PA (en) HIGHLY CONCENTRATED FORMULATIONS OF SOLUBLE Fc RECEPTORS
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
EA201590886A1 (ru) Замещенные производные индола
AR096150A1 (es) FORMULACIONES ALTERNATIVAS PARA POLIPÉPTIDOS DE FUSIÓN RECEPTOR DE FACTOR DE NECROSIS TUMORAL FUSIONADO A UN DOMINIO Fc (TNFR:Fc)
EP3085384A4 (en) Pharmaceutical composition with improved stability containing factor vii fusion protein